Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs
W Jiang, J Xia, S Xie, R Zou, S Pan, Z Wang… - Drug Resistance …, 2020 - Elsevier
Chemoresistance including intrinsic and acquired anticancer drug resistance continues to
be a primary hindrance towards curative cancer treatment. Therefore, deciphering the …
be a primary hindrance towards curative cancer treatment. Therefore, deciphering the …
Research on the economics of cancer-related health care: an overview of the review literature
AJ Davidoff, K Akif, MT Halpern - JNCI Monographs, 2022 - academic.oup.com
We reviewed current literature reviews regarding economics of cancer-related health care to
identify focus areas and gaps. We searched PubMed for systematic and other reviews with …
identify focus areas and gaps. We searched PubMed for systematic and other reviews with …
RETRACTED ARTICLE: LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
J Wang, J Gao, Q Chen, W Zou, F Yang… - OncoTargets and …, 2020 - Taylor & Francis
Wang J, Gao J, Chen Q, et al. Onco Targets Ther. 2020; 13: 9333–9347. At the authors
request, we the Editor and Publisher of OncoTargets and Therapy are retracting the …
request, we the Editor and Publisher of OncoTargets and Therapy are retracting the …
Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line–Indian consensus statement update (Under the aegis of Lung Cancer …
K Prabhash, A Vora, S Limaye, TP Sahoo… - Cancer Research …, 2021 - journals.lww.com
The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …
becoming increasingly complex, with the identification of driver mutations/rearrangements …
[HTML][HTML] APU-Net: An attention mechanism parallel U-Net for lung tumor segmentation
T Zhou, YL Dong, HL Lu, XM Zheng, S Qiu… - BioMed Research …, 2022 - hindawi.com
Lung cancer is one of the malignant tumors with high morbidity and mortality, and lung
nodules are the early stages of lung cancer. The symptoms of pulmonary nodules are not …
nodules are the early stages of lung cancer. The symptoms of pulmonary nodules are not …
[HTML][HTML] The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices
P Fabio, C Alessandro, S Stefania… - Acta Bio Medica …, 2019 - ncbi.nlm.nih.gov
Background: To date there exist no internationally recognised Good Manufacturing Practices
(GMP) that clearly outline universally accepted standards for manufacturing highly active or …
(GMP) that clearly outline universally accepted standards for manufacturing highly active or …
[PDF][PDF] 接受EGFR-TKIs 治疗的EGFR 突变阳性非小细胞肺癌患者预后预测列线图模型构建及验证
黄维佳， 曹健斌， 李逢昌， 李竞长… - 实用心脑肺 …, 2022 - boyuancaibian.oss-cn-beijing …
目的构建接受EGFR-TKIs 治疗的EGFR 突变阳性非小细胞肺癌(NSCLC) 患者预后预测列线图
模型, 并验证其预测价值. 方法选取2018—2020 年柳州市人民医院胸外科, 呼吸科 …
模型, 并验证其预测价值. 方法选取2018—2020 年柳州市人民医院胸外科, 呼吸科 …
[HTML][HTML] Comparing the cost-effectiveness of sintilimab+ pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with …
Y Shi, D Qian, Y Li, W Chen, M Bo… - Translational Cancer …, 2023 - ncbi.nlm.nih.gov
Background Pemetrexed plus platinum alone is the conventional first-line therapy for locally
advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable …
advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable …
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
CM Cramer-van der Welle, BJM Peters… - PharmacoEconomics …, 2021 - Springer
Abstract Background The Value-Based Health Care concept defines patient value as patient-
relevant outcomes divided by costs. The aim of the present study was to assess the …
relevant outcomes divided by costs. The aim of the present study was to assess the …
[PDF][PDF] Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib …
G Zhang, X Tang, X Zhang, X Qiu, Q Lai, J Li - Anti-Cancer Drugs, 2023 - journals.lww.com
The development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …
(TKIs) represents a paradigm shift in the treatment of lung cancer with EGFR mutations …